Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Market Access

Jazz and Lilly cancer drugs cleared for use by NHS

 April 21, 2026

Pharmaphorum

Jazz’s biliary tract cancer drug Ziihera and Lilly’s Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

Market AccessOncologyRead full story

Post navigation

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground →
← Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com